|
|
Identification, characterisation and discovery of putative lymphoma
markers using Protein Array Technology
PI: Derek Murphy
Project: Over
thirty types of lymphoma are now recognized, each of which requires its
own individual treatment. This makes the correct diagnosis of the
specific subtypes very important. Our collaborators at the Leukaemia Research Fund Immunodiagnostics Unit in
the John Radcliffe
Hospital, Oxford, are leaders in the field of
lymphoma diagnostic marker discovery, identification of new
cancer-associated proteins and developing antibodies against them.
We have developed a novel approach, using arrays containing thousands
of recombinant proteins, to both identify new potential disease markers
(e.g. serum profiling) and characterize antibody binding and
specificity. Similarly, we have demonstrated the use of protein arrays
to identify novel protein-protein interactions. In this project we are
establishing protein arrays as a tool for the identification of the
targets of potential lymphoma marker antibodies from the Oxford programme (including defining the specificity of
these potential markers) and for the discovery and characterisation
of new lymphoma serum biomarkers.
Further, a selection of the proteins recognised
by these antibodies can be screened against the arrays to identify
interactions of these proteins, gaining information towards delineating
the molecular pathways involved. To contribute to the discovery of
novel lymphoma-associated proteins, the protein arrays will be screened
with serum samples from patients and controls and the protein targets of
auto-antibodies present identified, purified and used to generate new
antibody markers. (Supported by SFI).
<< Return to Research Main Page
|
|
